Actively Recruiting
Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes
Led by Novo Nordisk A/S · Updated on 2026-04-24
80
Participants Needed
1
Research Sites
86 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical study is to find out how NNC0487-0111 affects, how the body uses insulin (a hormone that helps the body control blood sugar) and how well the pancreas works in people living with type 2 diabetes. There are 2 study treatments. Participants will get either NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
CONDITIONS
Official Title
Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female.
- Age between 18 and 75 years at the time of signing informed consent.
- Diagnosed with type 2 diabetes for at least 180 days before screening.
- On a stable daily dose of metformin at an effective or maximum tolerated dose for at least 90 days before screening.
- If using additional oral antidiabetic drugs, only stable doses of sodium-glucose cotransporter-2 inhibitors are allowed and must have been maintained for at least 90 days before screening.
- HbA1c between 6.5% and 9.5% if on metformin only, or between 6.0% and 9.0% if on metformin plus sodium-glucose cotransporter-2 inhibitors.
You will not qualify if you...
- Female who is pregnant, breastfeeding, planning to become pregnant, or of childbearing potential not using highly effective contraception.
- Diagnosis of type 1 diabetes.
- Significant body weight change (5% or more) or dieting attempts within 90 days before screening.
- Treatment with medications for type 2 diabetes or weight management other than those allowed within 90 days before screening, except short-term insulin treatment for up to 14 days or prior insulin for gestational diabetes.
- Treatment with a GLP-1 receptor agonist.
- Diabetic retinopathy or maculopathy requiring or expected to require treatment with retinal photocoagulation, vitrectomy, or anti-VEGF therapy.
- History or presence of cardiovascular disease including angina, myocardial infarction, stroke, cardiac failure, significant arrhythmias, or conduction disorders within 180 days before screening.
- Renal impairment with an estimated glomerular filtration rate less than 60 ml/min/1.73 m2 at screening.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany, 41460
Actively Recruiting
Research Team
N
Novo Nordisk
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here